Cleghorn Laura A T, Albrecht Sébastien, Stojanovski Laste, Simeons Frederick R J, Norval Suzanne, Kime Robert, Collie Iain T, De Rycker Manu, Campbell Lorna, Hallyburton Irene, Frearson Julie A, Wyatt Paul G, Read Kevin D, Gilbert Ian H
Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee , Sir James Black Centre, Dundee, DD1 5EH, U.K.
J Med Chem. 2015 Oct 8;58(19):7695-706. doi: 10.1021/acs.jmedchem.5b00596. Epub 2015 Sep 29.
There is an urgent need for new, brain penetrant small molecules that target the central nervous system second stage of human African trypanosomiasis (HAT). We report that a series of novel indoline-2-carboxamides have been identified as inhibitors of Trypanosoma brucei from screening of a focused protease library against Trypanosoma brucei brucei in culture. We describe the optimization and characterization of this series. Potent antiproliferative activity was observed. The series demonstrated excellent pharmacokinetic properties, full cures in a stage 1 mouse model of HAT, and a partial cure in a stage 2 mouse model of HAT. Lack of tolerability prevented delivery of a fully curative regimen in the stage 2 mouse model and thus further progress of this series.
迫切需要能够穿透血脑屏障的新型小分子,以靶向人类非洲锥虫病(HAT)中枢神经系统第二阶段。我们报告称,通过针对布氏布氏锥虫在培养物中筛选聚焦蛋白酶文库,已鉴定出一系列新型吲哚啉-2-甲酰胺作为布氏锥虫的抑制剂。我们描述了该系列的优化和表征。观察到了强效的抗增殖活性。该系列表现出优异的药代动力学特性,在HAT第一阶段小鼠模型中实现了完全治愈,在HAT第二阶段小鼠模型中实现了部分治愈。耐受性不足阻碍了在第二阶段小鼠模型中实施完全治愈方案,因此该系列无法进一步推进。